Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multiple antigen specific cell therapy - HengRui YuanZheng Biotechnology

Next Previous
Drug Profile

Multiple antigen specific cell therapy - HengRui YuanZheng Biotechnology

Alternative Names: Cytotoxic T-cell therapy - HengRui YuanZheng; Dendritic cell therapy - HengRui YuanZheng; MASCT I; MASCT-1; Multiple target antigen stimulating cell therapy-I; Multiple-antigen specific cell therapy-I; Neo-MASCT

Latest Information Update: 22 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HengRui YuanZheng Bio-Technology
  • Developer Beijing Cancer Hospital; HengRui YuanZheng Bio-Technology; SYZ Cell Therapy
  • Class Antineoplastics; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants; Programmed cell death 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Endometrial cancer; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Neurofibrosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma; Urogenital cancer
  • Phase I/II Non-small cell lung cancer; Solid tumours
  • Phase I Liver cancer
  • No development reported Gastric cancer

Most Recent Events

  • 17 Jul 2024 HengRui YuanZheng Bio-Technology plans a phase I/II for Liver cancer in 2025 (HengRui YuanZheng Bio-Technology pipeline, July 2024).
  • 29 Feb 2024 HengRui YuanZheng Bio-Technology plans a phase II trial for Soft tissue sarcoma (Metastatic disease, Late stage disease, Inoperable/Unresectable, Combination therapy, Recurrent, First line therapy) in China (parenteral) in February 2024 (NCT06277154)
  • 13 Nov 2023 HRYZ Biotech terminates phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy, Inoperable/Unresectable) in China (IV) (NCT03034304)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top